How Employers Are Handling GLP-1 Costs

About half of Americans get health insurance through a job, so for most working-age people the question “is Wegovy covered?” is really the question “did my employer decide to cover it?” In 2023 and 2024 the answer was increasingly yes. In 2026 and 2027 it is increasingly no, or yes with conditions.

This article walks through what the benefits surveys actually found, what employers are doing short of dropping coverage, and what your options look like if your plan changes. It is not medical advice and not benefits advice for your specific situation; your plan documents and your prescriber are the authorities on that.

It also does not tell anyone how to use a medication. Nothing here describes a dose, a titration schedule, when to start or stop a drug, or how to combine one with another. Those are set by the FDA-approved prescribing information and Instructions for Use for each product, by your own prescription, and by your provider. Where this article touches clinical territory at all, it reports what a label, guideline or published study says, with a citation.

Is employer coverage of GLP-1s going up or down?

Down, after several years of going up. The exact percentage depends entirely on which employers a survey counts, which is why the headline numbers look inconsistent.

Survey	Population surveyed	Finding
KFF 2025 Employer Health Benefits Survey	Firms with 5,000+ workers	43% covered GLP-1s for weight loss, up from 28% in 2024 [1]
KFF 2025	Firms with 200+ workers	19% covered them [1]
Business Group on Health 2027 Employer Healthcare Strategy Survey, released August 25, 2026	Employers from under 5,000 to over 100,000 workers	Share covering GLP-1s for weight loss fell from 72% in 2025 to 60% in 2026; 14% have already dropped or plan to drop for 2027 [2][4]
Business Group on Health GLP-1 survey, fielded February-March 2026 among 105 member employers	Large employers	Of those covering, 72% said they were likely to continue in 2027 and 10% likely would not [5]
Mercer	Employers with 500+ workers	44% cover them; 6% dropped in 2026; 5% plan to drop for 2027 [4]

A correction worth making explicitly, because secondary coverage repeats it wrongly: Business Group on Health’s 72%-to-60% decline runs 2025 to 2026, not 2025 to 2027. The separate 2027 figure from the same survey is the 14% who have already dropped coverage or plan to for 2027 [2][4].

Every one of those surveys points the same direction for 2027. The same August 2026 survey put employers’ predicted 2027 healthcare cost trend at a median 9.2% before plan design changes, up from 8.5% for 2026, with pharmacy now about 25% of total healthcare spend [2].

One finding deserves attention if you are hoping your employer will add coverage: KFF found that most employers not covering GLP-1s for weight loss said they were “not likely” to start within twelve months, and only 1% said they were “very likely” to [6]. Business Group on Health reached the same conclusion, reporting that companies not covering GLP-1s today are unlikely to add coverage in the future [5].

Why are employers pulling back?

The short answer is that use ran far ahead of forecasts, and the cost landed in the pharmacy budget.

Use exceeded expectations. KFF found that 59% of firms with 5,000 or more workers said GLP-1 use for weight loss was higher than expected, and 44% of firms with 1,000 to 4,999 workers said the same [7]. Between 64% and 66% of large firms said covering the drugs moderately or significantly increased their prescription drug spending [7].

The claims share roughly doubled in three years. GLP-1s accounted for 6.9% of employer pharmacy claims in 2023 and 11.4% in 2026, according to Mercer data cited by CNBC [8]. In 2025, GLP-1 drugs used for weight loss represented more than 10% of all annual prescription drug claims among US employer plans [9].

Overall health costs are climbing anyway. Mercer projected total US health benefit cost per employee to rise about 6.5% to 6.7% for 2026 [10], and Aon projects a 9.5% increase for 2027, pushing average per-employee cost above USD 19,000 [11]. GLP-1s are not the only cause, but they are the most visible new line item, and Business Group on Health found that nearly eight in ten employers say GLP-1s are a major contributor to rising health care costs [3].

The savings case is contested. The strongest recent causal evidence, NBER Working Paper 34678 by Coady Wing, Sih-Ting Cai, Daniel W. Sacks and Kosali I. Simon (January 2026), analyzed commercial claims for roughly 537,000 patients who started a GLP-1 between 2017 and 2022. It found that after five years GLP-1 initiation produced about USD 22,500 in GLP-1 spending and a statistically significant USD 6,800 increase in non-GLP-1 medical spending, rather than an offset [12]. In the first year the increase was USD 585, driven mainly by a USD 438 rise in outpatient costs, partly offset by a USD 189 fall in spending on other diabetes medicines [12]. Other observational studies reach friendlier conclusions, so the question is genuinely unresolved. But an employer reading that paper is not going to expect the drug to pay for itself.

People stop. Employers report that many patients discontinue after reaching a weight goal, which undercuts the long-run savings argument while leaving the employer with the acquisition cost [8].

The oral-pill problem

Here is something benefits managers are unusually blunt about: cheaper pills may raise, not lower, employer costs.

Business Group on Health found that 87% of surveyed employers expect the arrival of oral GLP-1s to increase overall demand for the drugs, while only 9% expect an accompanying price decrease [5]. A lower price per prescription multiplied by a much larger number of prescriptions can be a bigger bill.

That is exactly what IQVIA observed in the market: about two-thirds of Wegovy pill volume in early 2026 came from people who had never taken any GLP-1 [13]. From a public health standpoint that is expansion of treatment. From a plan sponsor’s standpoint it is a budget forecast that just moved.

What employers do instead of dropping coverage

Most employers that still cover GLP-1s have tightened the terms rather than removing the benefit. Business Group on Health’s 2027 survey documents the specific tools [2]:

• Biometric eligibility validation. 69% of surveyed employers verify eligibility using measured biometrics rather than self-report.
• Required lifestyle program participation. 45% require enrollment in a weight management program. KFF found 34% of covering firms require meeting with a dietitian, case manager or therapist, or joining a lifestyle program [1].
• Restricted prescribers. Some employers limit prescribing to designated providers, specialists or preferred clinical programs.
• Redirection to cash-pay. Increasingly, employers point workers to manufacturer direct-to-consumer prices instead of covering the drug through the pharmacy benefit [8].

None of these are clinical recommendations. They are plan design choices, and they vary enormously by employer.

Insurers dropping it for their own staff

A notable 2026 development is that several insurers and health systems dropped weight-loss GLP-1 coverage for their own employees, which sends a signal about the economics.

• Cigna stopped covering GLP-1 weight-loss drugs including Wegovy and Zepbound in its own employee health plan effective July 1, 2026, announced to staff on June 1 [14].
• Blue Cross Blue Shield of Massachusetts dropped obesity GLP-1 coverage for employer groups under 100 employees at the start of 2026 [9].
• Harvard Pilgrim Health Care and Blue Cross Blue Shield of Michigan both dropped weight-loss GLP-1 coverage in 2026 [9].
• HCA Healthcare, one of the largest US hospital systems, ended GLP-1 coverage for employees after usage rose 90% in a single year, directing workers toward manufacturer cash-pay programs [9].

Can an employer legally do this?

Yes. Federal law does not require employer health plans to cover weight-loss medication. The Employee Retirement Income Security Act, which governs most employer plans, does not mandate it, and courts have generally sided with plans on this question [9].

The most recent significant ruling came on February 19, 2026, in Whittemore v. Cigna Health and Life Insurance Co., when the US Court of Appeals for the First Circuit affirmed the dismissal of a proposed class action challenging a plan’s weight-loss drug exclusion as disability discrimination under Section 1557 of the Affordable Care Act [25][26].

Be precise about what the court did and did not decide, because this ruling is widely overstated. The First Circuit affirmed on narrower grounds than the district court: it held that the plaintiff had not plausibly alleged she was disabled as the Americans with Disabilities Act defines it, because her complaint did not show that her obesity “substantially limits” a major life activity [25][26]. The court did not hold that weight-loss drug exclusions are categorically lawful, and it did not decide whether obesity can ever qualify as a disability. A differently pleaded complaint could reach a different result, and the question remains open in other circuits.

Coverage rules can differ when a GLP-1 is prescribed for another approved indication. Semaglutide has FDA-approved uses beyond weight management, including type 2 diabetes, cardiovascular risk reduction and metabolic dysfunction-associated steatohepatitis, and tirzepatide has approvals in type 2 diabetes and obstructive sleep apnea. Whether a specific plan covers a specific drug for a specific diagnosis is a question for your plan documents and your prescriber, not for a general article.

The new channel: manufacturers selling straight to employers

The most structurally interesting response in 2026 came from a drugmaker, not an employer.

On March 5, 2026, Eli Lilly launched Employer Connect, a direct-to-employer platform routed through more than 15 independent program administrators rather than through a pharmacy benefit manager [15][16].

The USD 449 figure needs one qualification that most coverage drops. Lilly makes the Zepbound KwikPen available to network pharmacies at USD 449 across all doses, with no rebates. What the employer actually pays varies with its choice of pharmacy and program administrator, and what the employee pays out of pocket varies with the cost-share model the employer picks and the dispensing and service fees negotiated with the administrator [15]. USD 449 is the acquisition price at one point in the chain, not a guaranteed all-in monthly cost.

The named administrators at launch included 9amHealth, Andel, Calibrate Health, Crux Health, eMed, FlyteHealth, Form Health, Goodpath, GoodRx, Ilant Health, Mark Cuban Cost Plus Drug Company, Onsera Health, ReviveHealth, SALTA Direct Primary Care, Sesame, Teladoc Health, Transcarent and Waltz Health, with dispensing through pharmacies including HealthDyne and CenterWell [15]. Omada Health joined in May 2026 [17], and GoodRx launched an Employer Direct pathway that applies an employer’s contribution against the USD 449 price [18].

The pitch to employers is cost predictability: a known unit price, an employer-chosen subsidy level, and no rebate opacity. Purchaser Business Group on Health’s Lauren Remspecher told Reuters that many employers still feel they are not seeing the same savings through PBM deals that direct cash purchasers get [4]. That is the gap Employer Connect targets.

Meanwhile, the PBMs pushed back

The largest pharmacy benefit manager reversed course in 2026 in a way that expanded, rather than contracted, insured access.

CVS Caremark had dropped Zepbound from its standard commercial template formularies in May 2025 in favor of Wegovy [19]. On May 28, 2026, it announced Zepbound would return as an additional preferred option effective October 1, 2026, and that the new-to-market block on Foundayo would be removed effective June 1, 2026 for plans electing coverage [19].

Both Wegovy products keep preferred status, so the two manufacturers are now co-preferred [20]. CVS projected the restructured formulary would cut weight-management drug spending an additional 10% to 15% [21], and said eligible commercially insured patients could pay as little as USD 25 a month for Zepbound and Foundayo [22].

The practical consequence for employees: Lilly’s obesity products became covered by all three of the largest US pharmacy benefit managers [20]. Individual employers using Caremark formularies can still decide not to pay for them, which is the recurring theme of this whole article. The PBM decides what is on the menu; the employer decides whether to buy it.

What to do if your employer changes coverage

If you get a notice that your plan is dropping or restricting GLP-1 coverage, these are the paths people are actually using. Which one fits you is a question for your prescriber and your plan administrator.

1. Read the exact wording. Plans sometimes drop coverage for weight management while retaining it for other approved indications. The diagnosis on the prescription can matter.
2. Ask about the appeal process. Plans generally have a formal exception or appeals path, with deadlines.
3. Check manufacturer self-pay prices. In 2026, LillyDirect cash prices ran USD 299 to USD 449 a month, with better pricing tied to refilling within 45 days, and NovoCare ran an introductory USD 199 stepping up to USD 349 [8]. Wegovy pill self-pay ran USD 149 to USD 299 by dose [23].
4. Check savings offers if you still have commercial insurance. Both manufacturers run copay programs; eligibility rules exclude Medicare and Medicaid.
5. If you have Medicare Part D, the Medicare GLP-1 Bridge demonstration offers certain products at a flat USD 50 monthly copay through December 31, 2027, with eligibility rules that exclude people whose GLP-1 is prescribed for type 2 diabetes or obstructive sleep apnea [24].
6. Understand that a coverage letter is an insurance event, not a clinical finding. The FDA-approved labeling for these products describes chronic weight management, and the withdrawal extension of the STEP 1 trial reported that participants regained about two-thirds of their lost weight in the year after semaglutide was stopped, while SURMOUNT-4 reported substantial regain after tirzepatide withdrawal [27][28]. That is what the published evidence says about discontinuation; it is not a statement about your situation. Whether to continue, change or stop any medication is a decision for you and your prescriber, who know your diagnosis and history.

Where this is heading

Two forces are pulling in opposite directions, and both are strong.

Pulling coverage down: rising overall benefit costs, a contested savings case, high and still-growing utilization, and the arrival of pills that expand the eligible population.

Pulling access up: falling net prices, manufacturer direct channels that route around the benefit entirely, a large Medicare demonstration, and PBMs competing on obesity formulary placement for the first time.

The likely result is not that Americans take fewer GLP-1s. It is that fewer of them get the drug through a job-based pharmacy benefit, and more of them buy it the way they buy other things: at a posted price, from a retailer or a manufacturer, with the employer either subsidizing part of it or standing aside.

---

Sources

1. KFF, “2025 Employer Health Benefits Survey.” https://www.kff.org/health-costs/2025-employer-health-benefits-survey
2. Business Group on Health, “How Are Employers Managing GLP-1 Coverage Amid Rising Demand and Costs?” https://www.businessgrouphealth.org/topics/blog/how-are-employers-managing-glp-1-coverage-amid-rising-demand-and-costs
3. Fierce Healthcare, “Nearly 8 in 10 employers say GLP-1 coverage drives up benefit costs,” May 6, 2026. https://www.fiercehealthcare.com/finance/nearly-8-10-employers-say-glp-1-coverage-spiking-benefit-costs-business-group-health
4. Reuters, “Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases,” June 11, 2026. https://www.reuters.com/legal/litigation/some-us-employers-drop-coverage-glp-1-obesity-drugs-2027-use-increases-2026-06-11
5. SHRM, “1 in 10 Employers Likely Will Stop GLP-1 Coverage in 2027.” https://www.shrm.org/topics-tools/news/benefits-compensation/1-in-10-employers-likely-will-stop-glp-1-coverage-in-2027
6. Fisher Phillips, “Employer FAQs on the Rise of GLP-1 Drugs for Weight Loss and the Workplace Impact.” https://www.fisherphillips.com/en/insights/insights/employer-faqs-on-the-rise-of-glp-1-drugs-for-weight-loss-and-the-workplace-impact
7. Peterson-KFF Health System Tracker, “Perspectives from employers on the costs and issues associated with covering GLP-1 agonists for weight loss.” https://www.healthsystemtracker.org/brief/perspectives-from-employers-on-the-costs-and-issues-associated-with-covering-glp-1-agonists-for-weight-loss
8. CNBC, “Direct GLP-1 prescriptions are Walmart, Costco, Amazon weight-loss win,” August 1, 2026. https://www.cnbc.com/2026/08/01/glp-1-prescriptions-weight-loss-walmart-costco-amazon.html
9. Simplefill, “Employers Are Dropping GLP-1 Coverage,” 2026. https://simplefill.com/employers-dropping-glp1-coverage
10. Mercer, “Trump announces lower GLP-1 prices. Will employer plans see them too?” https://www.mercer.com/en-us/insights/us-health-news/trump-announces-lower-glp-1-prices-will-employer-plans-see-them-too
11. Health Exec, “Employer healthcare expenses could spike 9.5% in 2027, pressured by GLP-1s.” https://healthexec.com/topics/healthcare-management/healthcare-economics/employer-healthcare-expenses-could-spike-95-2027-pressured-glp-1s
12. National Bureau of Economic Research, Working Paper 34678, “Do GLP-1 Medications Pay For Themselves?” https://www.nber.org/system/files/working_papers/w34678/w34678.pdf
13. IQVIA, “The outlook for obesity from 2026 to 2030,” April 21, 2026. https://www.iqvia.com/locations/emea/blogs/2026/04/the-outlook-for-obesity-from-2026-to-2030
14. Reuters, “Cigna drops coverage of GLP-1 obesity drugs for its own employees,” June 2, 2026. https://www.reuters.com/world/cigna-drops-coverage-glp-1-obesity-drugs-its-own-employees-2026-06-02
15. Eli Lilly and Company, “Lilly Employer Connect platform launches with over fifteen independent program administrators,” March 5, 2026. https://investor.lilly.com/news-releases/news-release-details/lilly-employer-connect-platform-launches-over-fifteen
16. HR Brew, “What HR should know about Eli Lilly’s direct-to-employer offering,” March 12, 2026. https://www.hr-brew.com/stories/2026/03/12/eli-lilly-direct-to-employer-coverage
17. Omada Health, “Omada Health Joins Lilly Employer Connect,” May 7, 2026. https://investors.omadahealth.com/news-releases/news-release-details/omada-health-joins-lilly-employer-connect-expanding-its-access
18. GoodRx, “GoodRx to Expand Employer-Sponsored Access to Zepbound KwikPen.” https://investors.goodrx.com/news-releases/news-release-details/goodrx-expand-employer-sponsored-access-zepboundr-kwikpenr
19. CVS Health, “CVS Caremark delivers affordability and access to GLP-1 weight management medications with expanded coverage options,” May 28, 2026. https://www.cvshealth.com/news/company-news/cvs-caremark-delivers-affordability-and-access-to-glp-1-weight-management-medications-with-expanded-coverage-options.html
20. Healthcare Dive, “CVS obesity drug deal puts Lilly on equal footing with Novo.” https://www.healthcaredive.com/news/lilly-cvs-caremark-formulary-zepbound-foundayo-obesity-glp1/821364
21. Yahoo Finance, “CVS Caremark adds Zepbound and Foundayo to insurance coverage.” https://finance.yahoo.com/sectors/healthcare/articles/cvs-caremark-adds-zepbound-foundayo-112025031.html
22. Fierce Pharma, “CVS will cover Eli Lilly obesity products Zepbound and Foundayo.” https://www.fiercepharma.com/pharma/cvs-restores-coverage-eli-lilly-obesity-drugs-zepbound-foundayo
23. Novo Nordisk, “Financial report for the period 1 January 2026 to 30 June 2026,” August 4, 2026. https://attachment.news.eu.nasdaq.com/a0078e15b379bff5e3b0ffdbddb3d5075
24. National Council on Aging, “What Is the Medicare GLP-1 Bridge Program?” https://www.ncoa.org/article/expanding-access-to-weight-loss-medications-the-medicare-glp-1-bridge-program
25. Thomson Reuters EBIA, “First Circuit Rejects ACA Section 1557 Challenge to Plan’s Weight-Loss Drug Exclusion” (Whittemore v. Cigna Health & Life Ins. Co., 2026 WL 777418 (1st Cir. 2026)). https://tax.thomsonreuters.com/news/first-circuit-rejects-aca-section-1557-challenge-to-plans-weight-loss-drug-exclusion
26. HR Dive, “Worker did not plausibly argue obesity was a disability, 1st Circuit finds,” February 23, 2026. https://www.hrdive.com/news/cigna-obesity-disability-lawsuit-1st-circuit-maine/812855
27. Wilding JPH et al., “Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension,” Diabetes, Obesity and Metabolism, 2022. https://pubmed.ncbi.nlm.nih.gov/35441470
28. Aronne LJ et al., “Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial,” JAMA, 2024. https://jamanetwork.com/journals/jama/fullarticle/2826524